Tau tangles may abound in neurons, but they could leave an epigenetic imprint on a different cell—oligodendrocytes. So say scientists led by Nilüfer Ertekin-Taner at the Mayo Clinic in Jacksonville, ...
As the brain’s jumpy immune responders, microglia have the potential to ward off AD pathogenesis … or make it worse. On which side of this fine line they fall seems to change as disease progresses, ...
Comments Meet Tanycytes: Bridging Brain and Body, These Cells May Dispose of Tau 13 Mar 2026 ...
Blood tests for Alzheimer’s disease are rapidly transforming the way clinicians diagnose the disease. Still, some scientists urge caution when interpreting results, arguing that the meaning of a ...
Rarely do scientists discover a new pathogenic mutation for a sporadic disease. Even less often do they find one that explains half the cases. Pinning disease on a dinucleotide expansion? That’s a new ...
Contact Information Kellen Petersen, Ph.D. St. Louis, United States Professional Information InstructorWashington University in St. Louis https://kellenpetersen ...
Once more than 4 percent of tau molecules in a person’s blood are phosphorylated at residue 217, the clock starts ticking—toward the first symptoms of Alzheimer’s disease, that is. How long it might ...
As the brain’s fluid drainage systems become sluggish with age, troublemakers such as amyloid and tau aggregates start to build up. To flush out disease-causing detritus, neurosurgeons in China have ...
On November 24, Novo Nordisk announced that the GLP-1 mimetic semaglutide had failed to slow progression of Alzheimer’s disease in two Phase 3 trials. Even though the cat was out of the bag, ...
Transferrin-receptor shuttles distribute antibody cargo throughout the parenchyma, steering clear of ARIA-provoking vascular amyloid. Trontinemab is enrolling Phase 3 for early AD, announces plans for ...
As the trained killers of the immune system, cytotoxic T cells silently save our lives every day—vanquishing viruses before they can run amok, and putting nascent cancer cells out of business before ...
Talk about a closely watched study. Conference after conference, Roche scientists running the ongoing Brain Shuttle AD trial of trontinemab are dispensing morsels of news from sequential interim ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results